PBA
Paradigm Biocapital Advisors Portfolio holdings
AUM
$3.73B
1-Year Est. Return
133.76%
This Fund
S&P 500
1 Year Est. Return
+133.76%
AUM
$3.38B
AUM Growth
+$1.04B
(+44%)
Holding
39
Top Buys
| 1 | +$95.9M | |
| 2 | +$93M | |
| 3 | +$75.7M | |
| 4 |
CDTX
Cidara Therapeutics
CDTX
|
+$61.3M |
| 5 |
Agios Pharmaceuticals
AGIO
|
+$57.6M |
Top Sells
| 1 | +$85.3M | |
| 2 | +$84.2M | |
| 3 | +$57.3M | |
| 4 |
MoonLake Immunotherapeutics
MLTX
|
+$41.5M |
| 5 |
LENZ
LENZ Therapeutics
LENZ
|
+$23.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Nuvalent
NUVL
$7.85B
| $456M | 13.48% |
5,269,433
|
|
||
|
MRUS
2
DELISTED
Merus
MRUS
| $412M | 12.18% |
4,373,770
+91,816
|
|
||
3
Arcellx
ACLX
$6.6B
| $382M | 11.29% |
4,649,016
|
|
||
4
Revolution Medicines
RVMD
$19.7B
| $291M | 8.6% |
6,223,291
+130,000
|
|
||
5
Tarsus Pharmaceuticals
TARS
$3.26B
| $158M | 4.69% |
2,665,698
-310,401
|
|
||
6
Vaxcyte
PCVX
$8.63B
| $136M | 4.03% |
3,784,755
+411,918
|
|
||
|
ABVX
7
Abivax
ABVX
$8.88B
| $133M | 3.93% |
+1,564,196
|
|
||
8
Genmab
GMAB
$17.1B
| $117M | 3.46% |
+3,816,851
|
|
||
|
9
Agios Pharmaceuticals
AGIO
$1.67B
| $107M | 3.18% |
2,673,555
+1,531,044
|
|
||
10
Crinetics Pharmaceuticals
CRNX
$4.15B
| $106M | 3.14% |
2,550,774
+207,221
|
|
||
11
Edgewise Therapeutics
EWTX
$3.14B
| $100M | 2.96% |
6,170,131
+27,787
|
|
||
|
CDTX
12
DELISTED
Cidara Therapeutics
CDTX
| $92M | 2.72% |
+961,164
|
|
||
13
UroGen Pharma
URGN
$884M
| $84.1M | 2.49% |
+4,216,084
|
|
||
14
Scholar Rock
SRRK
$4.79B
| $74.8M | 2.21% |
2,009,745
+409,191
|
|
||
15
Janux Therapeutics
JANX
$808M
| $71.4M | 2.11% |
2,920,258
|
|
||
16
Olema Pharmaceuticals
OLMA
$1.85B
| $66.5M | 1.97% |
6,794,172
+30,000
|
|
||
17
Apogee Therapeutics
APGE
$4.63B
| $60.5M | 1.79% |
1,521,757
+563,127
|
|
||
18
Viridian Therapeutics
VRDN
$2.79B
| $56.3M | 1.67% |
2,609,353
-132,223
|
|
||
19
Alkermes
ALKS
$4.97B
| $51.6M | 1.53% |
1,719,334
+343,765
|
|
||
|
LENZ
20
LENZ Therapeutics
LENZ
$411M
| $50M | 1.48% |
1,073,461
-643,605
|
|
||
21
Pharvaris
PHVS
$1.75B
| $45.8M | 1.36% |
1,835,494
+772,583
|
|
||
22
Cogent Biosciences
COGT
$6.01B
| $45.3M | 1.34% |
3,156,398
-7,196,051
|
|
||
23
Ocular Therapeutix
OCUL
$2.34B
| $40.9M | 1.21% |
3,497,307
+76,967
|
|
||
24
BridgeBio Pharma
BBIO
$12.6B
| $35.5M | 1.05% |
684,277
-281,487
|
|
||
25
Erasca
ERAS
$4.39B
| $29.6M | 0.87% |
13,560,017
+1,652,835
|
|